Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study.

Urologic oncology·2026

Same author

Requirement for written informed consent and selection bias in a chart-review prostate cancer study.

American journal of epidemiology·2026

Same author

Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer.

BJU international·2026

Same author

Quantifying the Impact of Biochemical Recurrence After Radical Prostatectomy on Overall Mortality by Years of Life Lost: Results from the SEARCH Database.

European urology oncology·2026

Same author

Integrating NLP to Enhance Algorithmic Identification of Metastatic and Castration-Resistant Prostate Cancer in Large Claims-Based Studies.

Cancer medicine·2025

Same author

Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer.

JAMA network open·2025

Same journal

Methods for incorporating test result information within the high-dimensional propensity score framework: application in UK electronic health record data.

BMC medical research methodology·2026

Same journal

Sparse multi-way DMDC for longitudinal classification in high dimension low sample size data.

BMC medical research methodology·2026

Same journal

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

BMC medical research methodology·2026

Same journal

Comparative evaluation of interrupted time series analytical methods for healthcare quality improvement research: a Monte Carlo simulation study.

BMC medical research methodology·2026

Same journal

Methodological advances in claims-based dementia algorithms: integrating medication and clinical data for medicare populations.

BMC medical research methodology·2026

Same journal

An interpretable XGboost algorithm for predicting 30-day mortality in acute pancreatitis using routine biomarkers.

BMC medical research methodology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 4, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Accommodating heterogeneous missing data patterns for prostate cancer risk prediction.

Matthias Neumair¹, Michael W Kattan², Stephen J Freedland^3,4

¹Department of Life Sciences, Technical University of Munich, Freising, Germany. m.neumair@tum.de.

BMC Medical Research Methodology

|July 21, 2022

Summary

This summary is machine-generated.

This study developed an online tool for prostate cancer risk prediction, effectively handling missing patient data. The "available cases" method proved optimal for accommodating incomplete risk factor information.

Keywords:

Clinical risk prediction Missing data Prostate cancer Validation

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Related Experiment Videos

Last Updated: Sep 4, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Area of Science:

Biostatistics
Medical Informatics
Oncology

Background:

Missing risk factor data is a common challenge in clinical prediction models.
Heterogeneous data from multiple cohorts complicates risk prediction.
Developing tools that accommodate missing data is crucial for accurate predictions.

Purpose of the Study:

To compare logistic regression methods for handling missing risk factor data in multi-cohort studies.
To develop an online risk prediction tool that accommodates missing end-user data.
To optimize the use of available data in clinical risk prediction.

Main Methods:

Compared six logistic regression methods using data from ten Prostate Biopsy Collaborative Group (PBCG) cohorts.
Developed an online risk prediction tool utilizing the optimal missing data approach.
Validated the tool using an external European cohort and internal cross-validation.

Main Results:

The 'available cases' method, pooling individual patient data, performed best in external validation (AUC 75.7%).
This method showed superior calibration (CIL -2.9%) compared to imputation (CIL -13.3%).
The developed online tool requires serum PSA and age, with ten optional risk factors.

Conclusions:

Clinical risk prediction tools must optimize the use of available data, even with missing information.
Providing options for users with missing risk factors enhances tool utility.
The 'available cases' method is effective for developing robust risk prediction tools.